YingweiChen Ph.D.

Dr. Yingwei Chen focuses on patent prosecution and patent portfolio management worldwide in the biotechnology and pharmaceutical industries. Her practice includes preparation and prosecution of patent applications, strategic patent portfolio management, IP due diligence evaluations, freedom-to-operate analyses, patentability evaluations, patent invalidity analyses, and supporting the Firm's Biologics Price Competition and Innovation Act (BPCIA) practice.

Yingwei has worked with established companies, start-ups, and research institutions. She has experience with a wide range of technologies, including immunotherapies (vaccines, antibodies, and next-generation antibody platforms), gene therapies (viral or nonviral vector-based therapeutics), cell therapies (CAR-T, stem cell, and iPSC therapeutics), infectious disease prevention, diagnostics, and manufacturing (antibodies and vaccines).

Yingwei holds a Ph.D. in biochemistry and molecular biology. Prior to joining Jones Day, Yingwei served as principal scientist for more than seven years in the biotechnology industries, where her work focused on protein engineering for medical diagnostics and cancer therapy.

Yingwei conducted her postdoctoral research at the National Institutes of Health (NIH), where she investigated protein properties using biophysical techniques. During her Ph.D. research, she led the antibody section in a national institute, where she co-developed antibodies, diagnostic kits, and vaccines targeting infectious diseases. She served as an inspector in a vaccine phase III clinical trial, where more than 110,000 volunteers were vaccinated. She has authored and coauthored more than 30 peer-reviewed publications.